PL2672979T3 - Przeciwciała anty-cd4, w szczególności do zapobiegania chorobie przeszczep przeciw gospodarzowi (gvhd) - Google Patents

Przeciwciała anty-cd4, w szczególności do zapobiegania chorobie przeszczep przeciw gospodarzowi (gvhd)

Info

Publication number
PL2672979T3
PL2672979T3 PL11801972T PL11801972T PL2672979T3 PL 2672979 T3 PL2672979 T3 PL 2672979T3 PL 11801972 T PL11801972 T PL 11801972T PL 11801972 T PL11801972 T PL 11801972T PL 2672979 T3 PL2672979 T3 PL 2672979T3
Authority
PL
Poland
Prior art keywords
gvhd
antibodies
versus
host
disease
Prior art date
Application number
PL11801972T
Other languages
English (en)
Inventor
Stephan Fricke
Frank Emmrich
Nadja Hilger
Original Assignee
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. filed Critical Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V.
Publication of PL2672979T3 publication Critical patent/PL2672979T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0648—Splenocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL11801972T 2010-12-02 2011-12-02 Przeciwciała anty-cd4, w szczególności do zapobiegania chorobie przeszczep przeciw gospodarzowi (gvhd) PL2672979T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10015236A EP2471543A1 (en) 2010-12-02 2010-12-02 Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
PCT/EP2011/006060 WO2012072268A2 (en) 2010-12-02 2011-12-02 Tolerance induction or immunosupression to prevent in particular graft-versus-host-disease (gvhd) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
EP11801972.8A EP2672979B1 (en) 2010-12-02 2011-12-02 Anti cd4 antibodies to prevent in particular graft-versus-host-disease (gvhd)

Publications (1)

Publication Number Publication Date
PL2672979T3 true PL2672979T3 (pl) 2019-03-29

Family

ID=43903838

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11801972T PL2672979T3 (pl) 2010-12-02 2011-12-02 Przeciwciała anty-cd4, w szczególności do zapobiegania chorobie przeszczep przeciw gospodarzowi (gvhd)

Country Status (10)

Country Link
US (3) US9745552B2 (pl)
EP (3) EP2471543A1 (pl)
JP (2) JP6008863B2 (pl)
KR (2) KR101870277B1 (pl)
CA (1) CA2819520C (pl)
DK (2) DK2672979T3 (pl)
ES (2) ES2701760T3 (pl)
HU (2) HUE040300T2 (pl)
PL (1) PL2672979T3 (pl)
WO (1) WO2012072268A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
EP2931893A1 (en) * 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
US10556959B2 (en) 2014-11-07 2020-02-11 Xencor, Inc. Anti-CD39 antibodies and uses thereof
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
US20190262396A1 (en) * 2016-02-15 2019-08-29 Fraunhofer-Gesellschaft Zur Fõrderung Der Angeewandten Forschung E.V. Prevention of graft rejection by prior use of modified grafts
AU2019282248A1 (en) * 2018-06-08 2021-01-07 Imaginab, Inc. Antigen binding constructs to CD4
EP3957364A1 (en) * 2020-08-20 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
CN116693687B (zh) * 2023-08-03 2023-10-03 天津旷博同生生物技术有限公司 一种抗人cd25工程抗体及应用
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2026032970A1 (en) 2024-08-07 2026-02-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Cd4-specific chimeric antigen receptor and methods and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3850750T2 (de) * 1987-12-02 1994-12-22 Becton Dickinson Co Verfahren zur Verhütung von GVHD.
DE3828582A1 (de) * 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
DE3919294C2 (de) 1989-06-13 1998-04-23 Frank Prof Dr Emmrich Verwendung eines monoklonalen Antikörpers zur Behandlung einer Autoimmunerkrankung
SG88714A1 (en) 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
JP2822586B2 (ja) 1990-04-19 1998-11-11 富士ゼロックス株式会社 インクジェットプリンター
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
EP0840618B1 (en) * 1995-05-18 2003-04-23 Ortho-McNeil Pharmaceutical, Inc. Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
WO1999061065A1 (en) * 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US20010036664A1 (en) * 2000-03-10 2001-11-01 Robert Korngold L-leucyl-L-leucine methyl ester treatment of donor lypmhocyte infusions in bone marrow transplant patients
DK1454137T3 (da) 2001-12-11 2008-06-16 Biotectid Gmbh Anvendelse af en mærket ligand med specificitet for det humane CD4-molekyle
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
RU2007102055A (ru) * 2004-06-22 2008-07-27 Толерркс, Инк. (Us) Оптимизированное введение доз анти-cd4-антител для индукции толерантности у приматов
JP2008505645A (ja) * 2004-07-10 2008-02-28 アレクシオン ファーマシューティカルズ， インコーポレイテッド ガン細胞に特異的な抗体を見出すための方法およびそれによって見出される抗体
US8557533B2 (en) * 2007-02-01 2013-10-15 Helmut Jonuleit Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
JP5688734B2 (ja) * 2008-12-12 2015-03-25 国立大学法人 東京大学 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2471543A1 (en) 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
US20190262396A1 (en) * 2016-02-15 2019-08-29 Fraunhofer-Gesellschaft Zur Fõrderung Der Angeewandten Forschung E.V. Prevention of graft rejection by prior use of modified grafts

Also Published As

Publication number Publication date
WO2012072268A2 (en) 2012-06-07
EP2672979B1 (en) 2018-09-19
DK3351255T3 (da) 2020-10-19
JP2017039732A (ja) 2017-02-23
KR101739620B1 (ko) 2017-05-24
US20180051254A1 (en) 2018-02-22
EP2672979A2 (en) 2013-12-18
JP6008863B2 (ja) 2016-10-19
ES2701760T3 (es) 2019-02-25
KR20140027075A (ko) 2014-03-06
US10577588B2 (en) 2020-03-03
WO2012072268A3 (en) 2012-09-13
KR20160052809A (ko) 2016-05-12
US9745552B2 (en) 2017-08-29
HUE040300T2 (hu) 2019-02-28
JP6276818B2 (ja) 2018-02-07
KR101870277B1 (ko) 2018-06-26
DK2672979T3 (da) 2019-01-02
EP3351255B1 (en) 2020-08-26
WO2012072268A8 (en) 2013-03-28
CA2819520A1 (en) 2012-06-07
EP3351255A1 (en) 2018-07-25
US10227564B2 (en) 2019-03-12
US20130330334A1 (en) 2013-12-12
HUE051199T2 (hu) 2021-03-01
ES2824767T3 (es) 2021-05-13
JP2014501731A (ja) 2014-01-23
US20180030414A1 (en) 2018-02-01
EP2471543A1 (en) 2012-07-04
CA2819520C (en) 2021-06-22

Similar Documents

Publication Publication Date Title
HUE040300T2 (hu) Anti CD4 antitestek különösen graft-versus-host betegség (GVHD)
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL287270A (en) Anti-psgl-1 antibodies and their use
IL259436A (en) Antibodies against 3angptl and their uses
EP2758000A4 (en) COMPOSITE PROSTHETIC SHUNTING DEVICE
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
IL221288A0 (en) Therapeutic methods using anti-cd200 antibodies
HUE043977T2 (hu) Módszerek az abiotikus stressz toleranciájának növelésére a növényekben
GB201100610D0 (en) Improvements in ostomy bags
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2773039A4 (en) ELASTIC WAVE DEMULTIPLEXER
SG11201401411TA (en) Meditopes and meditope-binding antibodies and uses thereof
PL2621955T3 (pl) Przeciwciała anty-CEACAM6 i ich zastosowania
LT2753646T (lt) Anti-cd40 antikūnai ir jų panaudojimo būdai
EP2583224A4 (en) LOCATION CHECK PROCEDURE FOR LOCATION-BASED SERVICES
GB201016742D0 (en) Clostridium difficile antigens
ZA201206055B (en) Antibodies against cxcr4
EP2579820A4 (en) PRE-PACKED CORPORECTOM DEVICE FOR IMPROVING FUSION
GB201100609D0 (en) Improvements in ostomy bags
GB201114198D0 (en) Improvements in gasification
GB201014450D0 (en) Beverage filter
GB2483701B (en) Improvements in or relating to line-laying operations
GB201016809D0 (en) Improvements in relation to antibody binding
GB201022018D0 (en) Improvements in fluid collection devices
GB201010387D0 (en) Improvements in cone springs